“…Cancer is the second leading cause of death globally, with an estimated 9.6 million deaths in 2018 [ 1 ]. There is a need for the development and screening of anticancer therapeutics with non-conventional mechanisms of action (MoAs) [ 2 , 3 , 4 ]. Metallodrugs can provide rich chemistry and unique MoAs owing to their versatile structures, geometries and reactivities: examples include polypyridyl octahedral complexes of precious metals, some of which have been shown to target mitochondria and generate high levels of reactive oxygen species (ROS), while others can act as photosensitisers for use in photodynamic therapy [ 5 , 6 , 7 , 8 , 9 , 10 , 11 ], and half-sandwich complexes of metals from groups eight and nine (Fe, Ru, Os; Co, Rh, Ir) [ 12 , 13 , 14 , 15 , 16 , 17 , 18 ].…”